| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -11,793 | -37,137 | -4,538 | 2,453 |
| Depreciation | 19 | 20 | 19 | 39 |
| Stock-based compensation expense | 1,932 | 1,592 | 414 | 3,311 |
| Non-cash issuance of common stock | NaN | 250 | NaN | NaN |
| Loss on issuance of warrants | NaN | 0 | 0 | -75,644 |
| Loss on extinguishment of debt | -76 | NaN | NaN | NaN |
| Change in fair value of convertible notes | -8,727 | -17,549 | -1,877 | -3,485 |
| Change in fair value of warrants | -4,656 | 1,016 | 237 | -86,187 |
| Loss on derivative liability | 1,743 | 13,088 | NaN | NaN |
| Change in fair value of contingent consideration | -4 | 10 | -37 | -3,472 |
| Prepaid expenses and other current assets | -10 | -1,092 | -338 | 245 |
| Accounts payable | 539 | -1,583 | -1,382 | -2,003 |
| Accrued expenses and other liabilities | 700 | 331 | 481 | -3,018 |
| Other assets and liabilities | -71 | 940 | 5 | 7 |
| Net cash used in operating activities | -2,636 | -4,712 | -2,596 | -10,000 |
| Purchases of property and equipment | NaN | 0 | 0 | 4 |
| Net cash used in investing activities | NaN | 0 | 0 | -4 |
| Proceeds from issuance of shares, net-At Market Offering | NaN | 168 | NaN | NaN |
| Proceeds from issuance of at-the-market shares, net | NaN | NaN | NaN | 84 |
| Proceeds from issuance of shares, net-At Market Offering | NaN | NaN | 168 | NaN |
| Proceeds from issuance of public offering shares, net-Public Offering | NaN | 18,346 | NaN | NaN |
| Proceeds from pipe financing | 4,208 | NaN | NaN | NaN |
| Proceeds from issuance of public offering shares, net | NaN | NaN | NaN | 18,346 |
| Proceeds from issuance of shares, net-Public Offering | NaN | NaN | 18,346 | NaN |
| Proceeds from issuance of shares, net-Private Placement | NaN | 1,791 | NaN | NaN |
| Proceeds from issuance of shares, net | 1,665 | NaN | NaN | NaN |
| Net cash provided by financing activities | 5,873 | 1,791 | 84 | 18,430 |
| Net increase in cash | 3,237 | -2,921 | -2,512 | 8,426 |
| Cash and cash equivalents at beginning of period | 3,006 | 5,927 | 13 | NaN |
| Cash and cash equivalents at end of period | 6,243 | 3,006 | 5,927 | NaN |
AEON Biopharma, Inc. (AEON)
AEON Biopharma, Inc. (AEON)